Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease - Jernberg, Tomas; Payne, Christopher D.; Winters, Kenneth J.; Darstein, Christelle; Brandt, John T.; Jakubowski, Joseph A.; Naganuma, Hideo; Siegbahn, Agneta; Wallentin, Lars (European heart journal, 2006)
Keywords: Adult; Aged; Aspirin - administration & dosage; Aspirin - adverse effects; Biological and medical sciences; Cardiology. Vascular system; Coronary Artery Disease - drug therapy; Coronary heart disease; Drug Therapy, Combination; Female; Heart; Humans; Male; Medical sciences; MEDICIN; MEDICINE; Middle Aged; Piperazines - administration & dosage; Piperazines - adverse effects; Platelet Aggregation - drug effects; Platelet Aggregation Inhibitors - administration & dosage; Platelet Aggregation Inhibitors - adverse effects; Prasugrel Hydrochloride; Thiophenes - administration & dosage; Thiophenes - adverse effects; Ticlopidine - administration & dosage; Ticlopidine - adverse effects; Ticlopidine - analogs & derivatives; Human; Rate; CS-747; Cardiovascular disease; Thienopyridine; Acetylsalicylic acid; Coronary heart disease; Phlebology; Aggregation; Prasugrel; Platelet; Treatment; Trials; Clopidogrel; Circulatory system; Inhibition; Cardiology; Platelets; Comparative study; Responder